Factor VII coagulant activity, factor VII ?670A/C and ?402G/A polymorphisms, and risk of venous thromboembolism
نویسندگان
چکیده
منابع مشابه
Jaundice and factor VII deficiency in newborn
Resistance to thyroid hormone is an uncommon condition. We report the clinical and laboratory findings of a case with both resistance to thyroid hormone and, a reduced capacity to produce and respond to thyroid hormone. RTH is a disorder characterized by elevated circulating thyroid hormones, state of non-suppressed pituitary TSH secretion and refractoriness to hormone action in peripheral tiss...
متن کاملThrombosis and Factor Vii Activity
The tests for the coagulation time of the blood which are in general use have contributed little to the understanding of abnormal tendencies to thrombosis, as they are extremely insensitive to all but gross changes in the coagulation mechanism. A variety of techniques have been evolved to meet this defect. One group of these methods depends on the addition of an inhibitor, e.g., heparin, to the...
متن کاملMarburg I polymorphism of factor VII-activating protease and risk of venous thromboembolism.
The factor VII–activating protease (FSAP), a newly discovered serine-protease present in human plasma, has 2 main functions in hemostasis: it is a potent activator of prourokinase1 and accelerates coagulation by activating factor VII, independently of tissue factor.2 The FSAP Marburg I polymorphism (1601G A) was recently evaluated as a candidate risk factor for venous thromboembolism (VTE), sin...
متن کاملMarburg I polymorphism of factor VII-activating protease and risk of recurrent venous thromboembolism.
Whether a single nucleotide polymorphism (1601 G > A) in the factor VII-activating protease gene (FSAP Marburg I) is a risk factor for venous thromboembolism (VTE) is unclear. We investigated the relevance of the variant with respect to recurrentVTE. 854 patients with a first unprovoked VTE were followed for an average of 41 months after discontinuation of anticoagulation. Study endpoint was sy...
متن کاملPreparation of factor VII concentrate using CNBr-activated
Background: Factor VII concentrates are used in patients with congenital or acquired factor VII deficiency or treatment of hemophilia patients with inhibitors. In this research, immunoaffinity chromatography was used to purify factor VII from prothrombin complex (Prothrombin-Proconvertin-Stuart Factor-Antihemophilic Factor B or PPSB) which contains coagulation factors II, VII, IX and X. The a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thrombosis and Haemostasis
سال: 2007
ISSN: 1538-7933,1538-7836
DOI: 10.1111/j.1538-7836.2007.02620.x